Product Description
Lasmiditan is used to treat the symptoms of migraine headaches (severe throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light). Lasmiditan is in a class of medications called selective serotonin receptor agonists. Lasmiditan may work by stopping pain signals from being sent to the brain and stopping inflammation of the nerves that cause symptoms of migraine. Lasmiditan does not prevent migraine attacks or reduce the number of headaches you have. (Sourced from: https://medlineplus.gov/druginfo/meds/a620015.html)
Mechanisms of Action: 5-HT1F Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Croatia | Czech | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Korea | Lebanon | Lithuania | Mexico | Poland | Portugal | Saudi Arabia | Slovakia | Spain | Sweden | Turkey | United Arab Emirates | United States
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, China, France, Germany, India, Italy, Japan, Mexico, Netherlands, Puerto Rico, Romania, Russia, Spain, United Kingdom, United States
Active Clinical Trial Count: 8
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Migraine Disorders
Phase 1: Migraine with Aura|Migraine without Aura
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| PIONEER-PEDS1 | P3 |
Recruiting |
Migraine Disorders |
2026-11-01 |
80% |
2025-01-22 |
|
| H8H-MC-LAHW | P3 |
Recruiting |
Migraine Disorders |
2031-01-31 |
2025-05-02 |
Treatments |
|
| H8H-MC-LAHV | P3 |
Recruiting |
Migraine Disorders |
2029-11-30 |
2025-05-02 |
Treatments |
|
| PIONEER-PEDS2 | P3 |
Recruiting |
Migraine Disorders |
2028-01-01 |
82% |
2025-01-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| JapicCTI-205318 | P3 |
Planned |
Migraine Disorders |
2023-10-31 |
|||
| JapicCTI-205317 | P3 |
Planned |
Migraine Disorders |
2022-10-31 |
|||
| JapicCTI-194948 | P1 |
Active |
Migraine Disorders |
2020-07-31 |
|||
| CTR20222908 | P1 |
Recruiting |
Migraine with Aura|Migraine Disorders|Migraine without Aura |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/06/2024 |
News Article |
Organon Reports Results for the Second Quarter Ended June 30, 2024 |
|
05/02/2024 |
News Article |
Organon Reports Results for the First Quarter Ended March 31, 2024 |
|
01/03/2024 |
News Article |
Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor |
|
12/18/2023 |
News Article |
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines |